Tuhura Biosciences (NASDAQ:HURA) Q3 2026 Loss Narrower Than Expected as IFx-2.0 Phase 3 Remains in Focus
TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences Q3 EPS $(0.10) Beats $(0.14) Estimate
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
HURA: First Look at IFx-2.0 Deep-Seated Tumors
HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
TuHURA Reports Initial Data Showing Partial Responses In First Three Metastatic Merkel Cell Carcinoma Patients Treated With Ifx-2.0 Plus Keytruda
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
TuHURA Biosciences Secures US Patent For TBS-2025, Entitled ‘Anti-VISTA Antibodies And Uses Thereof’
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
FDA Gives Clearance To TuHURA Biosciences' IND Application For TBS-2025 VISTA-Inhibiting Antibody For Molecularly Defined Subsets Of AML And Other Blood-Related Cancers
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
HURA: Milestone Progression Over Next 12 Months
TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript
Citizens Reiterates Market Outperform on TuHURA Biosciences, Maintains $9 Price Target
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.